©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2025; 31(28): 105089
Published online Jul 28, 2025. doi: 10.3748/wjg.v31.i28.105089
Published online Jul 28, 2025. doi: 10.3748/wjg.v31.i28.105089
Fecal microbiota transplantation: A promising treatment strategy for chronic liver disease
Lei Ma, Meng-Han Zhang, Yi-Fan Xu, Yan-Xu Hao, Xuan-Xuan Niu, Yan Li, Hui-Chun Xing, Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Hui-Chun Xing, Center of Liver Diseases Division 3, Peking University Ditan Teaching Hospital, Beijing 100015, China
Author contributions: Ma L performed the data analysis and drafted the manuscript; Hao YX, Niu XX, and Li Y analyzed and interpreted the data; Zhang MH and Xu YF revised the manuscript critically for important intellectual content; Xing HC made substantial contributions to conception and design, and finally approved the version to be published.
Supported by National Key R&D Program of China, No. 2022YFC2304505 and No. 2021YFC2301801; the Beijing Municipal of Science and Technology Major Project, No. Z221100007422002; the Capital Funds for Health Improvement and Research, No. CFH-2024-1-2181; and Beijing Igandan Foundation, No. iGandanF-1082023-GSH011.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Hui-Chun Xing, MD, PhD, Chief Physician, Professor, Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. hchxing@sohu.com
Received: January 11, 2025
Revised: April 27, 2025
Accepted: July 2, 2025
Published online: July 28, 2025
Processing time: 194 Days and 19 Hours
Revised: April 27, 2025
Accepted: July 2, 2025
Published online: July 28, 2025
Processing time: 194 Days and 19 Hours
Core Tip
Core Tip: Fecal microbiota transplantation shows significant potential in treating chronic liver diseases by improving liver inflammation, biomarkers, lipid metabolism, and cognitive function. It works through the liver-gut axis, restoring intestinal microbiota balance. Despite promising results, challenges remain in donor selection, standard treatment protocols, and long-term safety. Ongoing clinical trials and further research are needed to refine protocols and establish standardized approaches for optimal efficacy and safety in managing chronic liver diseases.